#Atherosclerosis Epitranscriptomics

Cell type-specific dysregulation of m6A machinery in atherogenic phenotypes
#EndothelialCell ALKBH5
#SmoothMuscleCell WTAP
Mφ METTL3 YTHDF2

Re-analysis of scRNAseq Wirka's Nat Med 2019
pmc.ncbi.nlm.nih.gov/articles/PMC...

#THNO 2025
www.thno.org/v15p4785.htm

Single-cell transcriptomics #OxygenInducedRetinopathy #Angiogenesis

3 #Pericyte subsets

Col1a1 shRNA intravitreal P7 (onset of hyperoxia)▶️
⏬OIR avascular & neovascular tuft-like, SM α-actin+ mural cell-covered area

Also ⏬mural cell coverage of laser CNV

#THNO 2023
www.thno.org/v13p2515.htm

Fibroblasts⏫ #Lymphangiogenesis in transplanted heart🐭
BALB/c➡️C57BL/6J

Recipient pre-existing #LymphaticEndothelialCell➡️ 🫀allograft lymphangiogenesis

Ablation of Postn+ fibroblast (VEGFD Midline), or VEGFR3i➡️
⏬lymphangiogenesis
⏫allograft failure

#THNO 2024
www.thno.org/v14p1886.htm

#Tubulin #Angiogenesis

TUBB6 (β6V tubulin)
enriched in retinal #EndothelialCell #Pericyte
⏫in👤#AMD &🐭 #ChoroidNeoVascularization

Intravitreal siRNA Tubb6 ⏬ pathological angiogenesis in🐭 #OIR & 🐭laser CNV

YBX1 stabilizes TUBB6 ➡️
⏫Wnt3a/FZD8-Angiogenesis

#THNO 2025
www.thno.org/v15p2680.htm

Fibulin 7⬇️ROCK-Actin filamentation-MRTFA cascade➡️⬇️aortic #SmoothMuscleCell contractile phenotype in🐭hypertension (Angiotensin II)

Syndecan 4 as a binding partner & signaling antagonist of FBLN7

i.v. AAV9-SM22α-FBLN7▶️persistent FBLN7 protein 1.5-fold⏫in🐭aorta

#THNO 2024
www.thno.org/v14p7569.htm

#EndothelialCell MERTK (Efferocytosis receptor) is suppressed by #OscillatoryShearStress

MERTK KO🐭exhibit aggravated #Atherosclerosis
+accumulated apoptotic cells, mainly at intima

But how much is contributed by defect EC-mediated efferocytosis?🧐

#THNO 2024
www.thno.org/v14p2427.htm